HOUSTON, Sept. 16, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the company will present at the Virtual Oppenheimer
Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21st at 1:40 p.m. ET.
Soliton virtual presentation details include:
|
Date:
|
Monday, September
21st, 2020
|
|
Time:
|
1:40 pm ET
|
|
Location:
|
https://wsw.com/webcast/oppenheimer5/soly/2765943
|
Audio webcasts of Soliton' presentations will be available on
the investor relations section of Soliton's website at
https://ir.soliton.com/. Replays of the webcasts will be available
for 90 days after the date of the presentation.
Join our more than 200K
subscribers here to follow the Company:
https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of MD Anderson Cancer Center. The Company's first FDA cleared
commercial product will use rapid pulses of acoustic shockwaves as
an accessory to lasers for the removal of unwanted tattoos. The
Company is based in Houston,
Texas, and is actively engaged in bringing the Rapid
Acoustic Pulse ("RAP") device to the market. The Company believes
this "Soliton" method has the potential to lower tattoo removal
costs for patients, while increasing profitability to
practitioners, compared to current laser removal
methods. Soliton has completed a clinical study using the RAP
device to improve the appearance of cellulite and is investigating
potential additional capabilities of the RAP technology. The device
is currently cleared in the United
States only for use in tattoo removal and is not yet cleared
for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which statements involve risks and uncertainties. Forward-looking
statements in this press release include, without limitation, our
ability to participate in the Virtual Oppenheimer Fall Healthcare
Life Sciences & MedTech Summit. These statements relate to
future events, future expectations, plans and prospects. Although
Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the
Securities and Exchange Commission ("SEC"), including under the
heading " Risk Factors" in the Form 10-K for year ended
December 31, 2019 filed with the SEC
and as updated in our Form 10-Q filings and in our other filings
with the SEC. Any forward-looking statements contained in this
release speak only as of its date. Soliton undertakes no obligation
to update any forward-looking statements contained in this release
to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-presentation-at-virtual-oppenheimer-fall-healthcare-life-sciences--medtech-summit-2020-301131706.html
SOURCE Soliton, Inc.